Drug intelligence / Profile preview

MFC-0301

Development stage: Preclinical
Lead developer: Medific
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MFC-0301 is an investigational exosome-based therapeutic being developed by Medific for the treatment of solid tumors, with a primary focus on glioblastoma. The drug targets intrinsically disordered proteins (IDPs), which are implicated in cancer pathogenesis due to their lack of fixed structure and involvement in key cellular processes. As of June 2024, MFC-0301 is in preclinical development and has not yet entered clinical trials[1][3]. The specific mechanism of action, molecular target(s), and detailed pharmacological properties have not been publicly disclosed.

Other names: MFC 0301MFC0301MFC-0301

Beyond the preview

Go deeper on MFC-0301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MFC-0301.

Explore the full profile